patent/CN-101096359-B

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101096359-B

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02f24694b4445e31254823f04656311e
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C323-45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-381 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-695 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C279-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-417 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4168 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F7-18
filingDate	2006-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate	2012-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a227310081ed51c870452e689a32773 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_817abfed3e9b6bb77292c1391fa1e981 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6fdb9287a99244f2bea0d45a3acd607 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a61cc1a1cf03cb86ac7468362ac233d3
publicationDate	2012-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	CN-101096359-B
titleOfInvention	Polyaryl substituted methane oxygen or silica radical guanidine compound and preparation method and usage thereof
abstract	The invention discloses a compound as general formula (I), making method of the compound and application as nerve adjusting peptide U receptor modifier in the cardiovascular disease, immune system disease, metabolic disease (such as obesity)and cancer treatments.
priorityDate	2006-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004035566-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1559428-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6864268-B2
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465802045 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465559678 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID164048172 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465861815 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25020412

Total number of triples: 37.